We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurofilaments for NEDA Assessing in MS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03250169
Recruitment Status : Terminated (Under recruitment)
First Posted : August 15, 2017
Last Update Posted : February 25, 2022
Sponsor:
Information provided by (Responsible Party):
Queen Mary University of London

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.

Condition or disease Intervention/treatment
Multiple Sclerosis Drug: Alemtuzumab

Detailed Description:

Primary

  1. To evaluate the achievement of NEDA using blood and CSF neurofilaments in Alemtuzumab treated patients.

    Secondary

  2. To assess prognosis at the end of the study based on neurofilament status.
  3. To correlate neurofilament levels with clinical and MRI markers of disease activity.
  4. To evaluate the effect of Alemtuzumab on the profile of other CSF, blood, urine, faeces biomarkers of inflammation, neurodegeneration, neuronal sprouting and synaptogenesis, treatment activity and metabolic activity.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 21 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study
Actual Study Start Date : August 1, 2017
Actual Primary Completion Date : January 28, 2022
Actual Study Completion Date : January 28, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Alemtuzumab

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Drug: Alemtuzumab
    Licensed dose

Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Blood and CSF neurofilaments in Alemtuzumab patients over 24months [ Time Frame: 2 years ]
    Neurofilaments


Secondary Outcome Measures :
  1. Overall clinical response based on neurofilament response [ Time Frame: 2 years ]
    neurofilaments

  2. Neurofilament status and association with clinical and MRI markers of disease activity. [ Time Frame: 2 years ]
    Correlation index

  3. Longitudinal assessment of other biomarkers of inflammation & plasticity [ Time Frame: 2 years ]
    Correlation index


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Relapsing-remitting MS
Criteria

Inclusion Criteria:

  1. Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS).
  2. Age 18-55 years.
  3. EDSS score between 0-5.5.
  4. Commencing Alemtuzumab therapy at Neurology Infusion and Planned Investigation Unit, The Royal London Hospital, Ward 11D

Exclusion Criteria:

  1. A diagnosis of Secondary Progressive MS (SPMS) or other forms of progressive MS.
  2. Those unable to comply with study requirement
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03250169


Locations
Layout table for location information
United Kingdom
Queen Mary University of London
London, England, United Kingdom, E1 2AT
Sponsors and Collaborators
Queen Mary University of London
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Queen Mary University of London
ClinicalTrials.gov Identifier: NCT03250169    
Other Study ID Numbers: 011717
First Posted: August 15, 2017    Key Record Dates
Last Update Posted: February 25, 2022
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
 Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Alemtuzumab
Antineoplastic Agents, Immunological
Antineoplastic Agents